New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 3, 2014
10:29 EDTSPPIFDA approves Beleodaq for treatment of patients with PTCL
The FDA approved Beleodaq for the treatment of patients with peripheral T-cell lymphoma, PTCL, a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency’s accelerated approval program. Beleodaq and Folotyn are marketed by Spectrum Pharmaceuticals (SPPI).
News For SPPI From The Last 14 Days
Check below for free stories on SPPI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
10:02 EDTSPPISpectrum weakness attributed to FDA comment on Fusilev generics
The move lower in shares of Spectrum is being attributed to circulation of a Department of Health and Human Services document which states the FDA will be able to approve abbreviated new drug applications for levoleucovorin calcium, the trade name of Spectrum's Fusilev. Shares of Spectrum are down 4%, or 33c, to $7.42. Reference Link
August 7, 2014
16:03 EDTSPPISpectrum reports Q2 non-GAAP EPS 9c, may not compare with consensus (9c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use